GSK and J&J launch €150M VC fund with Index
This article was originally published in Scrip
Pharma giants GlaxoSmithKline and Johnson & Johnson have validated the asset centric investment approach of venture capitalist Index Ventures by cornerstoning a new €150 million fund. The pharma companies have each taken a 25% stake in the exclusively life sciences fund, with longstanding Index limited partners taking up the rest. Crucially, management of the fund will be the responsibility of Index Ventures, the pharma partners will only have an advisory role.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.